Johnson & Johnson

National $26 Billion Opioid Settlement with Distributors and J&J, Zero Executive Prosecutions

| Importance: 9/10

On February 25, 2022, Johnson & Johnson and three major drug distributors—McKesson, Cardinal Health, and AmerisourceBergen—finalized a $26 billion national settlement to resolve thousands of opioid lawsuits from states, counties, cities, and Native American tribes. Despite the record settlement …

McKesson Cardinal Health AmerisourceBergen Johnson & Johnson State Attorneys General opioid-crisis corporate-settlement accountability-failure pharmaceutical-distributors deferred-prosecution
Read more →

Oklahoma Wins $572 Million Verdict Against Johnson & Johnson for Opioid Public Nuisance

| Importance: 8/10

On August 26, 2019, Cleveland County District Judge Thad Balkman delivered a landmark $572 million judgment against pharmaceutical giant Johnson & Johnson for the company’s role in fueling Oklahoma’s opioid epidemic. The decision marked the first time a drugmaker was held culpable in …

Thad Balkman Johnson & Johnson State of Oklahoma opioid-crisis legal-accountability public-nuisance corporate-liability state-lawsuits
Read more →

Johns Hopkins Study Exposes Orphan Drug Act Gaming - Seven of Top 10 Drugs Exploiting Tax Breaks for Rare Diseases

| Importance: 9/10

Johns Hopkins researchers published findings demonstrating that pharmaceutical companies were systematically gaming the 1983 Orphan Drug Act by obtaining orphan drug designations—intended for treatments of rare diseases affecting fewer than 200,000 Americans—for blockbuster drugs generating billions …

Johns Hopkins University FDA AbbVie Roche Johnson & Johnson +4 more pharmaceutical-industry regulatory-capture tax-avoidance drug-pricing healthcare +2 more
Read more →

ACA Architect Liz Fowler Leaves White House for Johnson & Johnson After Industry-Friendly Healthcare Legislation

| Importance: 9/10

On December 5, 2012, Elizabeth “Liz” Fowler announced her departure from the White House to join Johnson & Johnson as head of global health policy, completing her third spin through the healthcare industry revolving door. Fowler had served as the chief architect of the Affordable …

Elizabeth Fowler Johnson & Johnson WellPoint Max Baucus Barack Obama +1 more revolving-door regulatory-capture healthcare lobbying pharmaceutical-industry +3 more
Read more →